New PhIII data in hand, Pfizer, Astellas hustle ahead in bid to expand US market for Xtandi
Pfizer $PFE just got some badly needed good news for its newly acquired cancer drug Xtandi.
After watching sales sink right after it acquired the therapy and all of Medivation for $14 billion, researchers say the drug cleared the Phase III study for non-metastatic, castration resistant prostate cancer. And at least one prominent analyst says that’s a big deal as Pfizer and its partners at Astellas look to build sales for this key therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.